A method for the recombinant production of cannabigerolic acid in a host organism may use a modified prenyltransferase. A modified prenyltransferase, a nucleic acid molecule that codes for the modified prenyltransferase, and a recombinant organism that includes the modified prenyltransferase and/or the nucleic acid are also disclosed here.

An expression system and method for producing a cannabinoid in algae are provided. The method includes expressing in an algae cell an enzyme for converting hexanoic acid to hexanoyl-CoA, enzymes for converting hexanoyl-CoA to olivetolic acid (OA), an enzyme for converting olivetolic acid (OA) to cannabigerolic acid (CbGA) and an enzyme for converting cannabigerolic acid (CbGA) to a cannabinoid.

Enzymes involved in cannabinoid biosynthesis are recombinantly expressed in a host cell. The host cell may be a prokaryote (e.g. Escherichia coli) or a eukaryote (e.g. Yarrowia lipolytica). The enzymes include a heterologous cannabigerolic acid synthase as well as additional enzymes involved in the biosynthesis of cannabinoid precursors such as geranyl diphosphate, olivetol, olivetolic acid, divarin and/or divarinic acid. Methods are provided for producing C5-cannabinoids and/or C3-cannabinoids by fermentation of the recombinant host cell. Alternatively, cannabinoids can be produced by biotransformation of cannabinoid precursors in recombinant cells or by disrupted recombinant cells.

A method for the recombinant production of cannabigerolic acid in a host organism may use a modified prenyltransferase. A modified prenyltransferase, a nucleic acid molecule that codes for the modified prenyltransferase, and a recombinant organism that includes the modified prenyltransferase and/or the nucleic acid are also disclosed here.

The present disclosure relates generally to methods and compositions for activating gamma-delta (GD) T cells. Such methods and compositions can be used to treat cancer.

Provided herein are cells, enzymes, and methods for improved cannabinoid production.

A prokaryote was genetically engineered to develop operationally simple, high-yield biosynthetic route for the production of farnesylated proteins. The recombinant organism was modified to express a target protein, a peptide sequence fused to the target protein at a C-terminus, and an alpha and a beta subunit of a prenyltrasferase. The prenyltrasferase may be farnesyltransferase or geranylgeranyl transferase, and the peptide sequence may comprise cysteine, two hydrophobic amino acids, and an amino acid having selectivity to farnesyltransferase or geranylgeranyl transferase.

The present disclosure relates generally to methods and compositions for activating gamma-delta (GD) T cells. Such methods and compositions can be used to treat cancer.